Cardiovascular health, heart failure, atherosclerosis, and cardiac research
460 articles
A Saudi Arabia survey reveals alarming gaps in ApoB testing knowledge among physicians and pharmacists, despite clear guideline recommendations.
A major NIH-backed study finds that daily low-dose aspirin does not extend healthy lifespan in older people, challenging a long-held preventive health belief.
A Phase 2 trial pits NNC0385-0434 tablets against evolocumab injections in high-risk cardiovascular patients — could a daily pill replace the shot?
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
A pilot trial explores whether intentionally inducing brief daily dyssynchrony via pacemaker can retrain failing heart muscle in humans.
Myqorzo (aficamten) wins FDA approval for symptomatic obstructive HCM, offering a novel cardiac myosin inhibitor option for patients.
Pfizer's landmark trial examines whether tafamidis can safely treat transthyretin amyloid cardiomyopathy, a progressive and often fatal heart condition.
A Cochrane review of 21 RCTs finds remote pharmacist care may improve adherence and lower blood pressure in NCD patients.
New JAMA research ties widely used food additives to elevated blood pressure and cardiovascular disease risk.
Phase 3 trial pits lerodalcibep against inclisiran to determine which PCSK9 inhibitor best cuts LDL in cardiovascular high-risk patients.
A Phase 2 trial tests once-daily oral resmetirom (MGL-3196) against placebo to reduce LDL-C in patients with inherited high cholesterol.
A completed Phase 3 trial evaluates obicetrapib added to maximum lipid-lowering therapy in patients with familial hypercholesterolemia and ASCVD.
